Celgene Corp (NASDAQ:CELG)

98.38
Delayed Data
As of Sep 16
 -0.02 / -0.02%
Today’s Change
58.59
Today|||52-Week Range
99.36
+53.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$70.0B

Company Description

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Contact Information

Celgene Corp.
86 Morris Avenue
Summit New Jersey 07901
P:(908) 673-9000
Investor Relations:
(908) 673-9969

Employees

Shareholders

Other institutional43.11%
Mutual fund holders33.02%
Individual stakeholders1.38%

Top Executives

Mark J. AllesChairman, President, CEO & COO
David V. ElkinsCFO, Principal Accounting Officer & Executive VP
Jay T. BackstromChief Medical Officer
Joseph S. CamardoSenior Vice President-Global Medical Affairs
Aijaz TobaccowallaChief Digital & Information Officer, Senior VP